WIPO logo
Mobile | Deutsch | English | Español | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Recherche dans les collections de brevets nationales et internationales
World Intellectual Property Organization
Recherche
 
Options de navigation
 
Traduction
 
Options
 
Quoi de neuf
 
Connexion
 
Aide
 
maximize
Traduction automatique
1. (WO2002083167) COMPOSITIONS THERAPEUTIQUES UTILISEES DANS LE TRAITEMENT D'UNE MALADIE DES VOIES RESPIRATOIRES
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique
CLAIMS

1. Use of a compound able to promote F actin formation in the manufacture of a medicament for the treatment of a disease of the respiratory tract.

2. Use according to claim 1, wherein the said compound is one or more of an ionic form of potassium, magnesium, calcium, cadmium, nickel, manganese, cobalt, lithium, zinc, ammonium polyamine or macrocyclic polyammonium salt.

3. Use according to claim 1 or claim 2, in combination with a DNA degrading enzyme.

4. Use according to claim 3, wherein promotion of F actin formation is effected before G actin binds to a DNA degrading enzyme.

5. Use according to any of claims 1 to 4, wherein the disease is a pulmonary disease characterised by the presence of viscous mucus .

6. Use according to any of claims 1 to 5, wherein the disease is cystic fibrosis.

7. Use of one or more salts selected from potassium, magnesium, calcium, cadmium, nickel, manganese, cobalt, lithium, zinc, ammonium polyamine and macrocyclic polyammonium salt in the manufacture of a medicament for the treatment of a pulmonary disease characterised by the presence of viscous mucus.

8. Use according to claim 7, wherein the said pulmonary disease is cystic fibrosis.

9. A pharmaceutical composition for the treatment of a pulmonary disease
characterised by the presence of viscous mucus, comprising:
(a) a compound able to promote F actin formation by shifting the equilibrium between G actin and F actin, and
(b) a DNA degrading enzyme
in respective proportions such as to provide a synergistic effect in the reduction of mucus viscosity, as a combined preparation for simultaneous, separate or sequential use.

10. A pharmaceutical composition according to claim 9, wherein compound (a) is selected from one or more of potassium, magnesium, calcium, cadmium, nickel, manganese, cobalt, lithium, zinc, ammonium polyamine and macrocyclic polyammonium salt.

11. A pharmaceutical composition according to claim 9 or 10, wherein the DNA degrading enzyme is a endonuclease.

12. A pharmaceutical composition according to any of claims 9 to 11, wherein the DNA degrading enzyme is DNAse I.

13. A pharmaceutical composition according to any of claims 9 to 12, wherein compound (a) is selected from potassium hydrogenophosphate K HPO and magnesium chloride MgCl2.

14. A pharmaceutical composition according to any of claims 9 to 13, for the treatment of cystic fibrosis.

15. A method of assessing the suitability of a composition according to any of claims 9- 14 for a patient suffering from pulmonary disease characterised by the presence of viscous mucus comprising the step of
contacting in vitro sputum from the patient with an agent which binds to G actin, determining the amount of G actin or determining a characteristic related to the effect of G actin in the sputum on Dnase activity.

16. A method according to claim 15 wherein the G actin binding agent is one or more compounds leading to an increased polymerisation of G actin in mucus such as ATP (adenosine 5' triphosphate), CAP III, Lipocortin-85, actin related protein 2, actin related protein 3, lyophaphatidic acid, oxytocin, recombinant Gcslp, LIM kinases, WASP proteins, Rho family GTP ases FH family proteins, VASP proteins, 5'-3-O- (thio)triphosphate (GTP gamma S), profilin, phalloidin, lysozyme, Arg-Gly-Asp tripeptide, Arg-Gly-Asp tripeptide containing peptides, CapZ, tropomodulin, phorbol esters, retinoids, surfactants protein fragmin, surfactant proteins A and D.

17. Use of an ionic form of potassium, magnesium, calcium, cadmium, nickel, manganese, cobalt, lithium, zinc, ammonium polyamine or macrocyclic polyammonium or a compound leading to an increased concentration of ionic potassium, magnesium, calcium, manganese, zinc, for promoting F actin formation by shifting the equilibrium between G actin and F actin in the manufacture of a medicament for the prevention or treatment of a disease induced by an excess of G actin or DNA.

18. Use according to claim 17, wherein the disease is the Wiskott Aldrich Syndrome.

19. Use of an ionic form of potassium, magnesium, calcium, cadmium, nickel, manganese, cobalt, lithium, zinc, ammonium polyamine or macrocyclic polyammonium or a compound leading to an increased concentration of ionic potassium, magnesium, calcium, manganese, zinc, for promoting F actin formation by shifting the equilibrium between G actin and F actin in a medicament for the prevention or treatment of a disease induced by an autoimmune response against

DNA.

20. Use according to claim 18, wherem the disease is Lupus Erythrematous.